Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074459 | 0.92 | LAP3 (0.44) | ATMCTSSCTSKSCN9AAKT1 | |
| SCHEMBL10078272 | 0.85 | KLK5 (0.40) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL10074341 | 0.85 | ATM (0.43) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL10074474 | 0.85 | ATM (0.43) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL6872873 | 0.83 | ATM (0.48) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL10077403 | 0.83 | ATM (0.41) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL10078269 | 0.83 | ATM (0.41) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL10074490 | 0.81 | ATM (0.40) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL12291410 | 0.81 | KLK5 (0.45) | ATMKLK5CTSSCTSKSCN9A | |
| SCHEMBL12849466 | 0.81 | KLK5 (0.42) | ATMKLK5CTSSCTSKSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | ATM 3559/4885KLK5 602/4885CTSS 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.